SEPTEMBER 30, 2008 - Proceeds to Fund Completion of Phase III Trial of Inhaled Cyclosporine following Lung Transplantation - APT Pharmaceuticals, a specialty drug development company focused on inhaled treatments for serious lung diseases, announced the completion of a $32.3 million Series B financing. The financing was led by Three Arch Partners and joined by additional new investors, InterWest Partners and Pinnacle Ventures. Existing investors Charter Life Sciences, Great Point Partners, Versant Ventures and Vivo Ventures also participated in the round... APT Pharmaceuticals' Press Release -
Oct 16, 2008
APT Pharmaceuticals : Phase III Trial of Inhaled Cyclosporine following Lung Transplantation
SEPTEMBER 30, 2008 - Proceeds to Fund Completion of Phase III Trial of Inhaled Cyclosporine following Lung Transplantation - APT Pharmaceuticals, a specialty drug development company focused on inhaled treatments for serious lung diseases, announced the completion of a $32.3 million Series B financing. The financing was led by Three Arch Partners and joined by additional new investors, InterWest Partners and Pinnacle Ventures. Existing investors Charter Life Sciences, Great Point Partners, Versant Ventures and Vivo Ventures also participated in the round... APT Pharmaceuticals' Press Release -
